The intragastric balloon market is projected to expand substantially by 2028 on account of rising adoption of minimally invasive treatment techniques in leading regions.

The COVID-19 pandemic-induced lockdown forced people out of their regular routines and into lower levels of physical activity, poor diet, and overeating, which resulted in a spike in the prevalence of obesity. As a result, mounting incidences of obesity and increasing preference of obese patients towards minimally invasive methods of treatment have augmented industry uptake in recent years.

Furthermore, industry participants have been focusing on product innovation and development to gain a competitive edge in evolving marketplaces, which has favorably impacted overall business dynamics. For instance, in March 2021, Apollo Endosurgery, Inc., a global provider of minimally invasive therapies, received the U.S. FDA approval for its novel intragastric balloon for treating patients with NASH (non-alcoholic steatohepatitis) dubbed the Orbera?(R) Intragastric Balloon.

To cite another instance, in November 2021, ReShape Lifesciences Inc., a leading manufacturer of minimally invasive medical devices to treat metabolic disease and obesity, launched ProCare Health Supplements. The novel line of supplements is intended to meet the nutritional needs of patients who have undergone medical weight-loss treatment and bariatric surgery.

The intragastric balloon market has been segmented on the basis of end-use, product, filling material, and region. With respect to product, the market has further been classified into triple intragastric balloon, single intragastric balloon, and dual intragastric balloon. The single intragastric balloon sub-segment is slated to progress at a considerable CAGR over the analysis period to reach around USD 35.6 million valuation by the end of 2028.

In terms of filling material, the intragastric balloon market has been bifurcated into saline-filled balloon and gas-filled balloon. In 2021, the gas-filled balloon sub-segment was valued at nearly USD 12.4 million and is primed to grow at a sturdy pace through the assessment timeline.

From the end-use perspective, the market has been categorized into clinics, hospitals, and ambulatory surgical centers. The intragastric balloon market from the hospitals sub-segment is anticipated to garner significant gains by 2028, expanding at a growth rate of about 12.6% through the study timeframe.

From the regional point of view, the Latin America intragastric balloon industry accounted for a share of nearly 3.7% in the overall industry revenue in 2021 and is poised to gain notable growth momentum over 2022-2028. The Middle East & Africa intragastric balloon market is set to register a sizable share in the overall market by 2028, growing at a CAGR of more than 10.5% over the estimated timeline.